vimarsana.com

Page 17 - முக்கியமான பராமரிப்பு அவசரம் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Protecting lungs from ventilator-induced injury

 E-Mail COLUMBUS, Ohio - An unfortunate truth about the use of mechanical ventilation to save the lives of patients in respiratory distress is that the pressure used to inflate the lungs is likely to cause further lung damage. In a new study, scientists identified a molecule that is produced by immune cells during mechanical ventilation to try to decrease inflammation, but isn t able to completely prevent ventilator-induced injury to the lungs. The team is working on exploiting that natural process in pursuit of a therapy that could lower the chances for lung damage in patients on ventilators. Delivering high levels of the helpful molecule with a nanoparticle was effective at fending off ventilator-related lung damage in mice on mechanical ventilation.

Why COVID-19 pneumonia lasts longer, causes more damage than typical pneumonia

Scientists identify target to treat COVID pneumonia and reduce severity Clinical trials with new experimental drug to begin early in 2021 Goal is to develop treatments that make COVID-19 no worse than a common cold First comparison between immune mechanisms driving COVID-19 pneumonia with other pneumonias CHICAGO - Bacteria or viruses like influenza that cause pneumonia can spread across large regions of the lung over the course of hours. In the modern intensive care unit, these bacteria or viruses are usually controlled either by antibiotics or by the body s immune system within the first few days of the illness. But in a study published in

DiosCURE to develop highly specific single-chain antibodies against SARS-CoV-2

Credit: © DiosCURE Therapeutics Core technology includes promising bivalent single-domain antibodies simultaneously targeting two surface structures of the viral spike protein. Lead candidates DIOS-202 and DIOS-203 are engineered for high potency and their potential to avoid the emergence of escape mutants. DIOS-202 and DIOS-203 entered into accelerated development to initiate clinical studies later this year. BONN, Germany, January 12, 2021 - DiosCURE SE announced a publication in Science describing its core technology of multivalent single-chain antibodies with a unique molecular mode-of-action to inactivate SARS-CoV-2 virions. An international team led by scientists at the University of Bonn developed and characterized the lead candidates, which are exclusively licensed by DiosCURE.

Laypeople have difficulty estimating severity of blood loss

Credit: Linkoping University When an accident occurs, the reactions of bystanders are important. Researchers have studied whether laypeople realise the severity of the situation when someone in their proximity begins to bleed, and whether they can estimate how much the person is bleeding. The results show a discrepancy related to the victim s gender: for a woman losing blood, both blood loss and life-threatening injuries were underestimated. The study has been published in the scientific journal PLoS One. Researchers from Linköping University and Old Dominion University in the United States wanted to study the ability of laypeople to visually assess blood loss, and what influences them when judging the severity of an injury.

KAIST Mobile Clinic Module helps to fill negative pressure ward shortage

Loading video. VIDEO: The MCM ward (450 m2 or 15m X 30m) accommodates four negative pressure bed rooms, nurse station, locker room, and treatment room. view more  Credit: KAIST A team from KAIST has developed a low-cost and ready-for-rapid-production negative pressure room called a Mobile Clinic Module (MCM). The MCM is expandable, moveable, and easy to store through a combination of negative pressure frames, air tents, and multi-function panels. The MCM expects to quickly meet the high demand for negative pressure beds in the nation and eventually many other countries where the third wave of COVID-19 is raging. The module is now ready to be rolled out after a three-week test period at the Korea Cancer Center Hospital.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.